2 years ago

MarraBio Secures £500,000 Seed Funding for Protein Alternative

  • MarraBio, a Newcastle-based spinout developing technology to instruct protein cells to grow in a certain way for research or commercial use, has secured £500,000 in seed funding

  • The company's protein alternative is both cheaper and has a longer shelf life than existing products

  • MarraBio is targeting biomedical research and therapy markets, along with the cultivated meat market

  • The seed round was led by Maven Capital Partners, Northstar Ventures, CPI Enterprises, and TCS Biosciences.

      • ProblemHealthcare

      "Bioactive proteins, essential for research and commercial applications, are expensive and have a short shelf life, limiting their accessibility and practicality."

      Solution

      "MarraBio offers a cheaper and longer-lasting alternative to bioactive proteins that can mimic their function, providing a more accessible and practical solution for biomedical research, therapy, and cultivated meat production."

      Covered on